North American long-acting bronchodilator market was $1.5 billion in 2018 and is anticipated to grow at a substantial rate of 2.0% during the forecast period. The major factors that are contributing significantly to the market growth include rising air pollution, growing geriatric population, and high healthcare expenditure. The US and Canada are the major economies of North America. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors augmenting the growth of the long-acting bronchodilator market in North America. The increasing demand for long-acting bronchodilator due to increasing COPD and asthma patients in the US have endorsed the approval of cohesive reimbursement policies in the US, is further fueling the growth of the market. The US is the major market due to greater healthcare expenditure and a higher prevalence rate of respiratory diseases.
To Request a Sample of our Report on North American Long-Acting Bronchodilator Market: https://www.omrglobal.com/request-sample/north-american-long-acting-bronchodilator-market
The North American long-acting bronchodilator market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, nasal, parenteral, and inhalation. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the high prevalence of asthma in the economies of the region such as the US and Canada. According to the Centers for Disease Control and Prevention (CDC) 2017, there are around 26 million asthmatics in the US, among which, nearly 18.9 million are adults and 7.1 million are children. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
(Get 15% Discount on Buying this Report)
A full Report of North American Long-Acting Bronchodilator Market is Available @ https://www.omrglobal.com/industry-reports/north-american-long-acting-bronchodilator-market
North American Long-Acting Bronchodilator Market Segmentation
By Route of Administration
- Oral
- Nasal
- Parenteral
- Inhalation
By Application
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
By End-User
- Homecare
- Hospitals and Clinics
Regional Analysis
- US
- Canada
Company Profiles
- Adamis Pharmaceuticals Corp.
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline PLC
- Novartis AG
- ResMed Corp.
- Pulmatrix Inc.
- Savara, Inc.
- Sunovion Pharmaceuticals
- Teva Pharmaceuticals Industries Ltd.
- Vitalograph Ltd.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
